The number of known novel platelet receptors/ligands that regulate the platelet activation cascade is growing. Recent studies demonstrated that scavengejr receptor class B, type I (SR-BI) is expressed on human and murine platelets. Importantly, reduced levels of platelet SR-BI expression are associated with increased platelet aggregation in patients. Total SR-Bl deficiency in mice on an apoE null background results in spontaneous myocardial infarction and premature death. Our preliminary studies showed that deficiency of SR-BI in murine platelets is also associated with remarkably increased platelet activation and aggregation in response to selected physiological agonists. In addition, we recently identified specific ligands for SR-BI that are potent inhibitors of integriri allbps activation andplatelet aggregation in vitro. Mechanisms linking SR-BI and allbB33 activation areniknown. Control of platelet reactivity is regarded as critical for prevention of acute cardiovascular events, thus the elucidation of mechanisms by which SR-BI may regulate integrin activation and whether it contributes to thrombotic events in vivo is important. It has been established that SR-BI may participate in signa ing events in several cell types. Moreover, CD36, a close relative of SR-BI, is associated in platelets wit i several protein-tyrosine kinases of theSrc family, Thus, we hypothesized that SR-BI-mediated signaling in platelets controls platelet integrin allbpS activation and, therefore, platelet aggregation and thrombosis. T ie long-term goal of this proposal is to determine the role platelet SR-BI is playing in thrombosis and to eluc date the exact molecular and cellular mechanisms of its contribution.
The specific Aims are:
Aim 1. To characterize the role cif SR-BI in integrin allb(33 activation andplatelet function in vitro.
Aim II. Toidentify the molecular signaling mechanisms linking SR-BI and activation of integrin allbft3 in platelets.
Aim III. Wewillseek to obtain evidence that platelet SR-BIplays a significant role in the regulation of platelet activation and thrombosis in vivo.
|Bledzka, Kamila; Bialkowska, Katarzyna; Sossey-Alaoui, Khalid et al. (2016) Kindlin-2 directly binds actin and regulates integrin outside-in signaling. J Cell Biol 213:97-108|
|Plow, Edward F; Das, Mitali; Bialkowska, Katarzyna et al. (2016) Of Kindlins and Cancer. Discoveries (Craiova) 4:|
|Sossey-Alaoui, Khalid; Plow, Edward F (2016) miR-138-Mediated Regulation of KINDLIN-2 Expression Modulates Sensitivity to Chemotherapeutics. Mol Cancer Res 14:228-38|
|Biswas, Sudipta; Xin, Liang; Panigrahi, Soumya et al. (2016) Novel phosphatidylethanolamine derivatives accumulate in circulation in hyperlipidemic ApoE-/- mice and activate platelets via TLR2. Blood 127:2618-29|
|Plow, Edward F (2016) The why's and wherefore's of this vascular biology section of Current Opinion in Hematology. Curr Opin Hematol 23:233-4|
|Meller, Julia; Rogozin, Igor B; Poliakov, Eugenia et al. (2015) Emergence and subsequent functional specialization of kindlins during evolution of cell adhesiveness. Mol Biol Cell 26:786-96|
|Liu, Jianmin; Das, Mitali; Yang, Jun et al. (2015) Structural mechanism of integrin inactivation by filamin. Nat Struct Mol Biol 22:383-9|
|Plow, Edward F; Qin, Jun (2015) The role of RIAM in platelets put to a test. Blood 125:207-8|
|Bialkowska, Katarzyna; Byzova, Tatiana V; Plow, Edward F (2015) Site-specific phosphorylation of kindlin-3 protein regulates its capacity to control cellular responses mediated by integrin Î±IIbÎ²3. J Biol Chem 290:6226-42|
|Xu, Zhen; Chen, Xue; Zhi, Huiying et al. (2014) Direct interaction of kindlin-3 with integrin Î±IIbÎ²3 in platelets is required for supporting arterial thrombosis in mice. Arterioscler Thromb Vasc Biol 34:1961-7|
Showing the most recent 10 out of 83 publications